AD Scientific Index
 Open Nav
Login Login Pricing & Plans Pricing & Plans
Nyanda Elias Ntinginya

Nyanda Elias Ntinginya

National Institute for Medical Research, Tanzania - Dar es Salaam / Tanzania
Others
AD Scientific Index ID: 6348524
-
person_outline Nyanda Elias Ntinginya's MOST POPULAR ARTICLES
1-) High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial The Lancet infectious diseases 17 (1), 39-49, 2017
2-) Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages Nature genetics 48 (12), 1535-1543, 2016
3-) Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label … The Lancet 385 (9979), 1738-1747, 2015
4-) Assessment of the novel T-cell activation marker–tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study The Lancet infectious diseases 14 (10), 931-938, 2014
5-) Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a … The Lancet Respiratory Medicine 7 (12), 1048-1058, 2019